Quick Answer
bioAffinity Technologies, Inc. reported Stockholders Equity of $7.28 million for the year ending 2025.
- bioAffinity Technologies, Inc. showed an increase of +179.7% in Stockholders Equity from 2024 to 2025.
- This data is from bioAffinity Technologies, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: -$14.16 million | Q3 2021: -$15.69 million | Q1 2022: -$16.72 million | Q2 2022: -$16.79 million | Q3 2022: $12.60 million | Q1 2023: $9.67 million | Q2 2023: $8.10 million | Q3 2023: $6.99 million | Q1 2024: $5.26 million | Q2 2024: $3.43 million | Q3 2024: $3.12 million | Q1 2025: $1.44 million | Q2 2025: -$2.14 million | Q3 2025: $8.90 million.
- Over the full 6 years of available data (2020 to 2025), bioAffinity Technologies, Inc.'s Stockholders Equity has grown by 148.3%.
- Historical annual values: Fiscal year 2025: $7.28 million | Fiscal year 2024: $2.60 million | Fiscal year 2023: $4.86 million | Fiscal year 2022: $11.04 million | Fiscal year 2021: -$15.79 million | Fiscal year 2020: -$15.07 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: